Results 11 to 20 of about 19,808 (220)

Role of Lutetium Radioligand Therapy in Prostate Cancer. [PDF]

Cancers (Basel)
Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive β-emitter 177Lu with Vipivotide Tetraxetan, a prostate-specific membrane antigen (PSMA)-binding ligand.
Książek I, Ligęza A, Drzymała F, Borek A, Miszczyk M, Francuz MR, Matsukawa A, Yanagisawa T, Fazekas T, Zapała Ł, Rajwa P.   +10 more
europepmc   +3 more sources

Actinium-225-PSMA versus lutetium-177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer: results of an observational study [PDF]

Frontiers in Oncology
BackgroundProstate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with Lutetium-177 (177Lu) and Actinium-225 (225Ac) is increasingly used in metastatic castration-resistant prostate cancer (mCRPC), but head-to-head prospective data ...
Tatiana Yu Kochetova, Mikhail B. Potievskiy, Lidia A. Nekrasova, Valeriy V. Krylov, Peter V. Shegai, Sergei A. Ivanov, Andrei D. Kaprin, Andrei D. Kaprin   +7 more
doaj   +2 more sources

RADIOLIGAND THERAPY IN LYMPHOMA: PAST, PRESENT AND FUTURE

Hematology, Transfusion and Cell Therapy
Summary: In the 80s, radiolabeled cells helped understand the pathology of hemato-oncology. In the 90s, pre-clinical trials evaluated radiolabeled immunotherapy with monoclonal antibodies (MoAbs) such as anti-CD20 agents labeled with Iodine-131 (Bexxar®)
Victor C.C.R. HERINGER, Ludmila S. ALMEIDA, Roberto C.D. BOLTON, Daniel C. PANCIEIRA, Samuel S MEDINA, Elba C.S.C. ETCHEBEHERE   +5 more
doaj   +4 more sources

Mechanistic Insights for Optimizing PSMA Radioligand Therapy [PDF]

Clinical Cancer Research, 2020
Abstract PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important factor explaining variability in clinical results. The ability to visualize the target with theranostics provides unique mechanistic insights.
Aravind S, Ravi Kumar, Michael S, Hofman
openaire   +2 more sources

Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection

Toxins, 2022
Botulinum Toxin injections into salivary glands (SG) up to a total dose of 100 units IncobotulinumtoxinA (IncoA) represent the treatment of choice for sialorrhea. However, BTX might also protect SG against sialotoxic radioligand cancer therapies.
Joerg Mueller, Thomas Langbein, Aditi Mishra, Richard P. Baum   +3 more
doaj   +1 more source

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Therapeutic Advances in Medical Oncology, 2022
Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC).
Isabel Heidegger, Claudia Kesch, Alexander Kretschmer, Igor Tsaur, Francesco Ceci, Massimo Valerio, Derya Tilki, Giancarlo Marra, Felix Preisser, Christian D. Fankhauser, Fabio Zattoni, Peter Chiu, Ignacio Puche-Sanz, Jonathan Olivier, Roderik C. N. van den Bergh, Veeru Kasivisvanathan, Andreas Pircher, Irene Virgolini, Giorgio Gandaglia   +18 more
doaj   +1 more source

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES

Вестник урологии, 2018
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. 177Lu-PSMA radioligand therapy is mainly used for patients with endstage prostate cancer. This report describes two
K. Kairemo, T. Joensuu
doaj   +1 more source

α_1L-adrenoceptors mediate contraction of human erectile tissue [PDF]

, 2018
α1-adrenoceptor antagonists can impact upon sexual function and have potential in the treatment of erectile dysfunction. Human erectile tissue contains predominantly α1A-adrenoceptors, and here we examined whether contractions of this tissue are mediated
Campbell, Alistair, Chapple, Christopher R., Chess-Williams, Russ, Davis, Beverley J., Naylor, Alisdair L., Sellers, Donna J., Sillar, David   +6 more
core   +1 more source

¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer [PDF]

Journal of Nuclear Medicine, 2017
177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective.
Fendler, Wolfgang Peter, Rahbar, Kambiz, Herrmann, Ken, Kratochwil, Clemens, Eiber, Matthias J.   +4 more
openaire   +3 more sources

Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering [PDF]

, 2016
Transplantation of human muscle precursor cells (hMPCs) is envisioned for the treatment of various muscle diseases. However, a feasible noninvasive tool to monitor cell survival, migration, and integration into the host tissue is still missing. METHODS:
Ametamey, Simon M., Betzel, Thomas, Dinulovic, Ivana, Eberli, Daniel, Handschin, Christoph, Haralampieva, Deana, Krämer, Stefanie D., Salemi, Souzan, Schibli, Roger, Stoelting, Meline, Sulser, Tullio   +10 more
core   +2 more sources